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Simple Summary: Breast cancer commonly migrates to the skeleton. Once patients have breast
cancer in their bones, their quality of life is poor. Research has shown that the environment and
structure of bone helps support metastatic breast cancer cell growth. Current models used in
laboratories to study breast cancer that has migrated to bone do not include all the components
of what happens in the human body. This is because technology in the past was limiting. Now,
however, a new technology exists, called three-dimensional (3D) bioprinting, that “prints” living
cells in geometries like the ones within the human body, to replicate a more realistic environment.
In cancer research, 3D bioprinting allows researchers to more closely replicate events that occur
when cancer cells migrate from a primary location to a secondary site, as well as model events in
the environment of the secondary site. 3D bioprinting may also be used instead of animal models in
some cases, and may speed up new drug discovery for cancer treatment.
Abstract: Breast cancer commonly metastasizes to bone, resulting in osteolytic lesions and poor
patient quality of life. The bone extracellular matrix (ECM) plays a critical role in cancer cell metastasis
by means of the physical and biochemical cues it provides to support cellular crosstalk. Current
two-dimensional in-vitro models lack the spatial and biochemical complexities of the native ECM
and do not fully recapitulate crosstalk that occurs between the tumor and endogenous stromal cells.
Engineered models such as bone-on-a-chip, extramedullary bone, and bioreactors are presently
used to model cellular crosstalk and bone–tumor cell interactions, but fall short of providing a
bone-biomimetic microenvironment. Three-dimensional bioprinting allows for the deposition of
biocompatible materials and living cells in complex architectures, as well as provides a means to
better replicate biological tissue niches in-vitro. In cancer research specifically, 3D constructs have
been instrumental in seminal work modeling cancer cell dissemination to bone and bone–tumor cell
crosstalk in the skeleton. Furthermore, the use of biocompatible materials, such as hydroxyapatite,
allows for printing of bone-like microenvironments with the ability to be implanted and studied
in in-vivo animal models. Moreover, the use of bioprinted models could drive the development of
novel cancer therapies and drug delivery vehicles.
Keywords: bioprinting; breast cancer; metastasis; bone; tissue engineering; 3D modeling; tumor
microenvironment; extracellular matrix
1. Introduction
Bone is a unique organ that provides, among other things, structural support and
protection for the body. The bone, including the extracellular matrix (ECM), is continu-
ously remodeled whereby components of the ECM are modified, secreted, or degraded [1].
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The skeleton is composed of a variety of cells, including osteoblasts, osteocytes, osteo-
clasts, fibroblasts, endothelial cells, and mesenchymal stromal cells [2,3]. These cells are
surrounded by organic and inorganic components such as type I collagen and apatite
nanocrystals [2–4]. These organic and inorganic components constitute the bone matrix
which is capable of providing biochemical and physiological cues that regulate bone
modeling and mechanotransduction [3].
The skeleton is an attractive site for cancer cell dissemination and colonization due
to its unique molecular and structural properties [5]. Although prognosis is excellent in
patients with early non-invasive disease, 5-year mortality rates with treatment exceed 80%
once cancer has invaded the bone [6]. Normal bone processes, such as bone remodeling,
produce a plethora of growth factors and cytokines that are strong chemoattractants for
metastatic cancer cells [7–11]. Once in the bone, metastatic cancer cells hijack the endoge-
nous stromal cells in the bone microenvironment, including osteoblasts and osteoclasts, to
remodel the bone matrix, leading to a disorganized basement membrane and disrupted
cellular crosstalk, which ultimately promote tumor progression [12–14]. Thus, understand-
ing the interactions between the ECM and metastatic cancer cells is crucial in order to
both regulate and prevent metastatic cancer cell growth in bone. However, the study of
cancer cell dissemination, seeding, colonization, and survival in bone is complicated by the
vast structural and physiological complexities of the organ. Most model systems currently
available only account for select aspects of the niche; thus, a combination of techniques is
frequently utilized to wholly recapitulate events that occur during bone–tumor crosstalk.
Two-dimensional (2D) in-vitro cell culture environments have arisen as important
platforms for the study of cancer cell proliferation, migration, and invasion as well as
cancer cell response to therapeutic treatment. Although simple and low cost, the planar
geometry and non-physiologic composition (i.e., tissue culture plastic) of 2D cultures can
induce variable cellular morphologies and aberrant gene expression [15–17] that impact
the behavior and cellular crosstalk of endogenous bone and tumor cells [15,18]. Moreover,
mechanical cues translated by the microenvironment are absent [3]. Importantly, Bissell
and colleagues discovered that normal breast epithelial cells required interactions with
the basement membrane, as present in three-dimensional (3D) cultures, to display and
maintain their normal phenotype. Otherwise, the normal breast epithelial cells behaved
similarly to tumor cells when grown in 2D cultures [19]. Thus, such models inadequately
represent the spatial, biochemical, and mechanical complexities of the native 3D tumor
microenvironment, severely limiting their interpretation in the study of metastatic disease
to the bone.
Recognizing these shortcomings, investigators are now developing 3D bone microen-
vironments such as bioreactors [20–26], scaffolds [27,28], extramedullary bone [29,30],
and bone-on-a-chip [31,32] models for metastatic cancer research. Such novel systems
allow for more relevant material composition and spatial relationships among cells and,
in some cases, provide similar mechanical forces. However, these systems face individual
challenges including reproducibility, scale, and ability to manipulate matrix biochemical
composition and structural integrity, and can be difficult to seed with cells for culture [33].
Thus, a gold standard model for the study of cancer metastasis to bone remains elusive.
3D bioprinting, an evolving technology, may help to facilitate such research. A novel
biofabrication technique that yields reproducible, biomimetic 3D environments composed
of cells and native biomaterials, 3D printing offers distinct advantages over prior 2D and
3D cell culture models. ECM composition and matrix geometry and stiffness, as well as cell
density and position, are all controllable parameters in bioprinted 3D scaffolds, supporting
cellular proliferation, migration, phenotype development, and matrix and biochemical
factor production [16]. 3D constructs can achieve biophysical characteristics similar to
the native tissue microenvironments, allowing for the study of cancer progression and
tumorigenesis [34]. Thus, 3D bioprinting may provide a more robust solution, yielding
biomimetic microenvironments for the study of cell–cell and cell–matrix interactions at the
forefront of cancer research.
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In this review, we focus on cancer metastases to bone and provide an overview of
current 2D and 3D in-vitro culture model systems, as well as 3D in-vivo and ex-vivo model
systems to study cancer metastases to bone. We review the applications and limitations
of current technologies, which include the inability of current models to wholly represent
the spatial, biochemical, and mechanical complexities of the native 3D tumor microenvi-
ronment, causing limited interpretation of results generated in these systems. We next
discuss an emerging technology called 3D bioprinting. 3D bioprinted bone-mimetic mi-
croenvironments offer distinct advantages over current 2D and 3D technologies, including
reproducibility and the ability to incorporate native biophysical properties of the ECM,
including cellular composition, stiffness, and geometry. As a result of these and other
advantages, 3D bioprinting has the potential to elevate into the next generation current
models in cancer research that mimic the bone–tumor niche.
2. Gross Anatomy of Bone and Bone Physiology
Bone is a metabolically active and dynamic organ that supports many body functions,
including regulation of calcium blood levels, providing structural support, and protecting
internal organs. To accomplish these and other functions, bone is composed of three main
cell types: osteoblasts, osteoclasts, and osteocytes. Osteoblasts, the cells that synthesize
new osteoid matrix, account for 4–6% of total cells in bone. Osteoblasts are derived from
mesenchymal stromal cells present in the bone marrow [35]. After stimulation with bone
morphogenetic proteins and growth factors, mesenchymal stromal cells proliferate to
form pre-osteoblasts, which then differentiate into mature osteoblasts capable of matrix
synthesis and deposition [36]. Newly formed bone is composed of type I collagen and
non-collagenous proteins (proteoglycans and other extracellular matrix proteins) (~22%),
hydroxyapatite (~70%), and water (~8% by weight) [35,37,38].
Osteoclasts, on the other hand, are the cells responsible for bone resorption. Os-
teoclasts account for 1–4% of total cells in the bone, and are derived from bone mono-
cytes [39,40]. Bone marrow monocytes (i.e., precursor osteoclasts) express Receptor Acti-
vator for Nuclear factor Kappa beta (NF-κB)(RANK) on their cell surface, which binds to
Receptor Activator for Nuclear factor Kappa beta Ligand (RANK-L) on osteoblasts to elicit
osteoclastogenesis [41]. Several single-nucleated osteoclasts then fuse together to form
one mature, multi-nucleated bone-resorbing osteoclast [41]. Upon subsequent activation,
osteoclasts carry out a complex degradation process to secrete matrix degradation enzymes
and resorb bone. This process exposes bones’ organic matrix via degradation by cathepsin
K and additional cysteine proteinases, lysozymal enzymes, phosphatases, and matrix
metalloproteinases at the osteoclast–bone interface [41–46]. As bone is resorbed, growth
factors stored in the bone matrix, including transforming growth factor-beta (TGF-B), in-
sulin growth factor (IGF), and bone morphogenetic proteins (BMPs), are released into the
microenvironment [47].
Osteocytes help to regulate the activities of osteoblasts and osteoclasts via mechan-
otransduction, and represent ~90–95% of cells in the bone [48,49]. Osteocytes are formed
when osteoblasts become terminally differentiated and embedded in the bone matrix.
Osteocytes reside in small cavities, called lacunae, which transmit signals to bone cells,
including osteoblasts and osteoclasts, via tiny channels called canaliculi [49]. These signals
regulate nutrient exchange in bone, as well as bone remodeling and sensation of mechanical
stimuli [3,50–53]. As a result of their ability to sense mechanical load in the bone, osteocytes
have earned the nickname the “mechanosensors of bone” [54–56].
3. Bone Remodeling during Disease
Bone resorption and deposition are held in a tightly regulated, homeostatic balance
in which there is no net bone loss or gain. However, this balance is upset in pathological
conditions, including infection (osteomyelitis), osteoarthritis, and bone metastatic can-
cers [57–60]. In each of these conditions, and especially in osteolytic disease related to
cancer, osteoclasts are overstimulated to degrade bone. Osteoblasts do not deposit new
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bone; thus resulting in net bone loss [61]. In brief, osteomyelitis is a severe bone infection,
caused by the bacterium Staphylococcus aureus, which can be fatal [62,63]. Osteomyelitis
typically occurs from chronic inflammation as a result of osseointegrated implants (e.g.,
dental implants or femoral implants (i.e., artificial hip)) [64–66]. Osteomyelitis involves the
internalization of S. aureus by osteoblasts, permitting S. aureus to evade immune detection
and cause sustained inflammation [67]. Upon internalization of S. aureus, osteoblasts in-
crease their production of inflammatory cytokines, including interleukin-6 (IL-6), monocyte
chemoattractant protein-1 (MCP-1), regulated on activation normal T cell expressed and
secreted (RANTES), and macrophage inflammatory protein-1 alpha (MIP-1 alpha), as well
as factors that stimulate osteoclastogenesis, including granulocyte-colony stimulating fac-
tor (G-CSF), RANK-L, and interleukin-8 (IL-8), among others [68–74]. Sustained infection
leads to a reduction in osteoblast proliferation and eventual osteoblast death. Subsequently,
bone is resorbed at an increased rate by osteoclasts, leading to sustained bone loss [74].
Osteoarthritis is another bone disease characterized by chronic inflammation that impacts
osteoblast function. In osteoarthritis, osteoblasts overexpress inflammatory cytokines,
including IL-8, IL-6, vascular endothelial growth factor (VEGF), and prostaglandin E2
(PGE2), among others [59,60,75]. This results in a reduction of osteoblast bone deposition,
and an imbalance in bone remodeling that results in sustained bone resorption. [76,77].
Interestingly, many of the same cytokines and inflammatory factors overexpressed by
osteoblasts during osteomyelitis and osteoarthritis have also been known to be overex-
pressed during bone invasion by metastatic cancer cells, including breast, prostate, lung,
and multiple myeloma [7,26,78–82].
4. Bone Is a Favored Site of Cancer Metastasis
Bone is a preferential site of cancer metastasis [8,9]. In an attempt to explain directional
tropism of disseminated cancer cells for specific organs in the body, Stephen Paget made
the following statement in 1889: “When a plant goes to seed, its seeds are carried in all
directions; but they can only live and grow if they fall on congenial soil [83]”. As suggested
by Paget, disseminated tumor cells are the “seeds” and the bone niche, rich in growth
factors, neovascularization factors, and cytokines, is the “congenial soil” necessary for
cancer cell growth [84]. Paget’s “seed and soil” hypothesis also explains the preferential
metastasis of breast, prostate, lung, and multiple myeloma disseminated cancer cells to the
bone. Furthermore, mounting evidence has implicated the cells of the bone responsible for
remodeling, the osteoblasts and osteoclasts, as key players in bone metastatic cancer cell
progression, including cancer cell homing to and seeding in bone, dormancy, cancer cell
re-activation, and contribution to macrometastatic lesion growth [85,86].
Once shed from a primary tumor, disseminated tumor cells enter the circulation,
ultimately traveling to large blood vessels found in the bone called vascular sinusoids.
Blood flow within the sinusoids is sluggish, allowing for normal movement of immune,
hematopoietic, and lymphoid cells into and out of the bone. This slow blood flow also
enables cancer cells to easily invade bone simply due to the normal physiology [8,87]. The
vascular sinusoids are the main entry point for disseminated tumor cells into the bones,
with the majority of metastases occurring at the ends of long bones, including the femur,
where there is a high rate of metabolic activity due to bone turnover by the osteoblasts
and osteoclasts.
4.1. Breast Cancer Cells Preferentially Metastasize to Bone
Approximately 20-30% of breast cancer patients will develop metastatic lesions, with
~15% of those being bone metastases [88,89]. Approximately 50% of these metastases
will involve bone as a primary secondary tissue, with nearly 80% being secondary or
recurring metastatic sites [82,90–92]. Once breast cancer invades bone, the relative 5-year
survival rate falls to less than 10% [90]. Lesions in the bone that form as a result of bone
metastatic breast cancer are predominantly osteolytic in nature, however, some lesions can
also be mixed lytic and blastic [10,87,91–93]. During the formation of osteolytic lesions,
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osteoclasts are constitutively activated to resorb bone, and osteoblasts do not deposit new
bone, resulting in sustained bone degradation. This phenomenon has been described
as the “vicious cycle” of breast cancer metastases to bone [9,25,94]. Occurring during
advanced tumor progression, metastatic breast cancer cells produce parathyroid hormone-
related protein (PTHrP), which stimulates osteoblasts to produce increased amounts of
RANK-L. Osteoblasts that overexpress RANK-L bind to the receptor RANK on osteoclast
precursors, stimulating osteoclastogenesis and increased bone resorption. Growth factors
stored in bone are released, including TGF-beta, which are used by cancer cells to produce
additional PTHrP [9,94], ultimately leading to sustained bone resorption and osteolytic
lesion formation. Bone pain, fractures, hypercalcemia, and spinal cord compression subse-
quently occur [9,95,96]. Clinically, patients with osteolytic lesions are treated with drugs
such as bisphosphonates that block the activity of osteoclasts, thus reducing bone degra-
dation [97–100]. However, these drugs are not curative for the lesions already present;
currently, no therapeutics are available that have the sole purpose to directly stimulate new
bone deposition by osteoblasts.
4.2. Multiple Myeloma Metastases to the Bone
Multiple myeloma is another cancer that preferentially metastasizes to bone [101,102].
Approximately 70% of patients presenting with multiple myeloma have bone metastases
upon diagnosis. Over time, over 90% of patients with multiple myeloma will develop
bone metastases during the course of their disease [103]. The vast majority of these metas-
tases will be osteolytic in nature, with bone being resorbed at a rate greater than it is
deposited. Multiple studies by Roodman and colleagues have determined this is due to
metastatic multiple myeloma cell suppression of osteoblast differentiation via a variety of
factors [104–110]. At present, two main treatment strategies are being evaluated either in
pre-clinical or clinical trials for the treatment of osteolytic metastases due to bone metastatic
multiple myeloma. First, in pre-clinical models, treatment with an antibody to sclerostin,
a Wnt/beta-catenin antagonist, reduced osteolytic lesion formation by 60% compared to
wild-type mice. In addition, in tumor-bearing mice with a genetic deletion of sclerostin,
there was a 50% increase in trabecular bone volume as well as an increase in the number
of osteoblasts compared to tumor-bearing, wild-type mice [106]. Furthermore, as part of
a phase I/II clinical trial, an inhibitor of DKK1, which is also involved in the Wnt signal-
ing pathway, was found to increase osteoblast differentiation and calcium deposition in
co-cultures of osteoblasts plus multiple myeloma cells in-vitro. That same DKK inhibitor
increased both trabecular bone volume and Wnt/beta-catenin signaling (crucial for os-
teoblast differentiation) in tumor-bearing mice when compared to placebo [111]. Taken
together, these results suggest that the inhibition of sclerostin and/or inhibitors of DKK1
may be promising tools to promote osteoblast activity, leading to increased subsequent
bone deposition in multiple myeloma bone disease.
4.3. Prostate Cancer Colonization of the Skeleton
Prostate cancer has a predilection for bone metastases. Greater than 80% of patients
with late-stage prostate cancer will develop bone metastases [9]. As opposed to other
cancers with strong tropism for the bone, the vast majority of metastatic lesions that occur
as a result of prostate cancer are osteoblastic in nature in which there is an excess of
bone deposition [112]. This is due to prostate cancer cells preferentially homing to the
ends of long bones where osteoblasts predominantly reside, leading to increases in both
osteoblast and prostate cancer cell proliferation [80,113]. Interestingly, newly formed bone
is disorganized, typically with low density, and is weak in strength [114,115]. This is due
to a malalignment of osteoblasts along a collagen matrix, leading to the production of bone
with a spongy structure as opposed to a hard and compact lamellar structure [116,117].
There are some reports, however, of bone metastatic prostate cancer lesions being mixed or
osteolytic [118,119].
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Similar to the “vicious cycle” of breast cancer metastases to the bone, bone metastatic
prostate cancer cells are involved in a cycle that promotes excessive bone deposition by
osteoblasts and continued proliferation of metastatic prostate cancer cells. Prostate can-
cer cells in the bone produce growth factors, including TGF-beta and IGF-1, as well as
bone morphogenetic proteins that drive osteoblasts to deposit new bone [81,95,120,121].
In turn, bone resorption by osteoclasts is suppressed, leading to sustained net bone de-
position [94,122]. In addition, activated osteoblasts overexpress inflammatory cytokines,
including IL-6, IL-8, MCP-1, and VEGF, that fuel metastatic prostate cancer cell growth in
bone [123]. A number of clinical trials are underway to treat osteoblastic lesions associated
with bone metastatic prostate cancer. In a phase I/II clinical trial, atrasentan, an antagonist
to the endothelin receptor A, reduced bone pain, slowed metastatic prostate tumor growth,
and resulted in a significant decrease in median time to disease progression when com-
pared to placebo [124,125]. In addition to atrasentan, Radium-223, an alpha particle emitter
that preferentially accumulates at sites rich in osteoblast activity, has proven to be a promis-
ing therapeutic for patients with bone metastatic prostate cancer. In pre-clinical models,
tumor-bearing mice exposed to Radium-223 had reduced bone growth, and preserved bone
volume and architecture [126].
4.4. Lung Cancer Metastasizes to the Skeleton
Lung cancer is another cancer that has a tropism for the bone, although less so than
breast cancer, prostate cancer, and multiple myeloma; lung cancer metastasizes to the bone
approximately 34.3% of the time [127]. While exact mechanisms for preferential metas-
tasis of lung cancer to bone are unclear, recent data implicate growth factors including
TGF-beta [128], cytokines and chemokines such as stromal-derived factor-1 (SDF-1) and
CXCR4 [129], and matrix metalloproteinases [129] that help drive lung cancer metastases
to bone. Of the many types of lung cancer, small cell lung cancer and non-small cell lung
cancer present mainly with osteolytic bone metastases in the spine and ribs [130–132]. Ad-
ditional data suggest that lesions associated with bone metastatic lung cancer can also be
mixed osteolytic and osteoblastic [130–132]. Clinically, markers of bone turnover, including
osteopontin, collagen type I, and bone sialoprotein, can be used as biomarkers for the
evaluation of bone metastatic lung cancer progression in human patients [133–140]. Osteo-
pontin in particular has been associated with an aggressive lung cancer phenotype whereby
increased osteopontin expression promotes lung cancer cell migration and invasion in bone
via increased epithelial-to-mesenchymal transition [141,142].
5. Models to Investigate Tumor-Bone Cell Interactions
5.1. Model Systems for Early Cancer Cell Dissemination to Bone
Upon dissemination to bone, a cancer cell will either proliferate to form a metastatic
lesion, or the cancer cell may enter a proliferatively quiescent or dormant state [143–145].
Sometimes also named “metastatic latency” [85], cellular dormancy can be defined as
either proliferative arrest or a state of balanced proliferation and apoptosis where there
is no net growth. In many situations, this is an adaptive response to microenvironmental
stress at a secondary site whereby disseminated tumor cells must respond to unknown
signals from the niche in order to survive [143]. Over time, dormant cancer cells become
reawakened, leading to cancer cell proliferation and the formation of macrometastases
in bone. At present, there is no model available that fully recapitulates all of the steps of
early human cancer cell dissemination to bone. While a number of pre-clinical models are
available that recapitulate specific steps of established disease, efforts to specifically study
earlier events in bone metastatic cancer progression, especially early dissemination to bone,
initial cancer cell seeding of bone, and events associated with metastatic latency, have
been hampered by a lack of mouse and ex-vivo model systems due to substantial technical
limitations [146]. Most importantly, there are no immune-competent mouse models capable
of recapitulating all steps of the metastatic cascade available to investigate the role of the
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immune system during disease progression. As a result, knowledge of the early events of
disease progression is severely limited.
Presently, only a handful of studies have attempted to investigate early steps of cancer
metastasis to bone. Of those, osteoblasts in the endosteal bone niche have been identified
as key mediators of cancer cell seeding. Scimeca et al. assessed human tissue samples
of benign breast lesions, breast-infiltrating carcinomas, and bone metastatic breast cancer
lesions [147]. The authors found a large number of breast cancer cells that underwent
epithelial-to-mesenchymal transition (EMT) in the infiltrating carcinomas, which corre-
sponded to a large number of breast–osteoblast-like cells that were positive for RANKL
expression as well as the vitamin D receptor. These breast–osteoblast-like cells were also
discovered in matched bone metastases [147]. These data suggest that osteoblasts and
osteoblast-like cells may be used as an early predictor of bone metastatic breast cancer.
Bodenstine et al. attempted to describe mechanisms that regulate osteoblast populations
during the early stages of bone metastatic breast cancer [148]. An intratibial injection
model was used to introduce osteoblasts plus bone-tropic breast cancer cells into the tibia
to assess tumor growth. In mice injected with cancer cells alone (control), tumors that
formed were smaller in size and remained contained in the bone cavity. By comparison,
breast cancer cells co-injected with osteoblasts formed large palpable tumors nearly double
the size of those formed with cancer cells injected alone, that migrated into the extra-
osseous space [148]. These data suggest intracellular crosstalk between osteoblasts and
bone metastatic cancer cells is important in cancer cell progression. However, while the
mouse model used may not be fully representative of early-stage events, it may still help
shed light on crosstalk that occurs between osteoblasts and metastatic breast cancer cells
in bone.
Our laboratory additionally utilized a mouse model of intratibial injection to study
interactions between osteoblasts and bone-tropic breast cancer cells in early disease progres-
sion. We identified a subset of osteoblasts present in the bone–tumor niche that regulate
breast cancer progression in bone by producing inhibitory factors that reduce breast cancer
cell growth [85]. We called this subset “educated” osteoblasts (EOs). Remarkably, tumors
formed in mouse bones in the presence of EOs were smaller and grew at a slower rate
than tumors composed of naive osteoblasts. We identified candidate proteins that distin-
guish “educated” osteoblasts (EOs) from naïve osteoblasts both in-vivo and ex-vivo. Using
these markers, we interrogated human patient samples of bone metastatic breast cancer
and identified EOs in patients with estrogen receptor positive (ER+) breast cancer [85,93].
Moreover, we demonstrated that exposure to EO conditioned medium reduced breast
cancer cell proliferation and led to a reduction in the number of cells in the S phase of the
cell cycle of both triple negative (TN) and ER+ breast cancer cells in-vitro. Furthermore,
direct co-culture with EOs increased TN and ER+ breast cancer expression of p21 compared
to cultures with naïve osteoblasts [85]. Similar to our findings in bone metastatic breast
cancer, Lawson et al. found that osteoblasts and osteoclasts in the bone were capable of
promoting (osteoblasts) or reawakening (osteoclasts) multiple myeloma cells from prolifer-
ative quiescence using an intravenous injection syngeneic mouse model as well as in-vitro
analyses [86]. The authors used intravital imaging to track single multiple myeloma cells as
they entered the bone niche and found that when fluorescently labeled multiple myeloma
cells directly engaged with osteoblasts, myeloma cell growth was suppressed [86]. The
authors recapitulated this in-vitro, whereby exposure to the conditioned medium of or co-
culture with murine osteoblasts increased the number of dormant multiple myeloma cells.
Conversely, when exposed to osteoclast-precursor conditioned media, multiple myeloma
cells exhibited increased proliferation and growth [86]. Interestingly, daily injection of
soluble RANK-L into tumor-bearing mice resulted in a reduction of dormant multiple
myeloma cells and subsequent increase in osteoclastogenesis and bone resorption. In two
additional studies, osteoblast expression of TGF-beta and Gas6 [149], as well as BMP7 [150],
maintained bone metastatic prostate cancer cells in a dormant state, whereas reduction
of those factors promoted prostate cancer cell growth. Thus, these data suggest engage-
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ment with osteoblasts either via direct or indirect means is key in the regulation of bone
metastatic cancer cell progression.
5.2. Models to Investigate Late-Stage Metastatic Cancer Cell Invasion, Colonization, and Survival
in Bone
Currently, there are no models available, in-vitro, ex-vivo, in-vivo, or otherwise, that
fully recapitulate all the steps of the human bone metastatic cascade. This is mainly due
to extensive technical hurdles and limitations, limited available human cell lines, limited
immune-competent models, and sustaining long-term cell growth of primary human
stromal cells [151–154]. As a result, multiple experimental models are used to investigate
specific aspects of the metastatic cascade, with each mainly designed to investigate a
specific stage of metastasis. Often, a combination of model systems is used to answer
a given experimental question. For example, we and others have used complimentary
approaches to investigate breast cancer metastasis in bone, including, but not limited
to, multiple human cell lines [155,156], extended culture bioreactors [156], poly-ether-
urethane foam scaffolds [157], biocompatible printed scaffolds [33], and novel engineered
organotypic models [154].
5.2.1. In-Vivo Models of Cancer Metastasis to Bone
In-vivo mouse models are a common pre-clinical assay to study a variety of steps of
the bone metastatic cascade. Syngeneic mouse models refer to murine cancer cells injected
into mice (i.e., same genetic background as the host), whereas xenograft models describe a
host that is genetically distinct from the cancer cells inoculated (i.e., human cancer cells
inoculated into mice). Each model has its own advantages and disadvantages: syngeneic
models permit the analysis of an immune-competent system, as well as allow investigation
between inoculated cells and endogenous stromal cells within the microenvironment [158].
However, there are proteins and genes that are not analogous between humans and
mice (e.g., IL-8 (human) and MIP-2 (murine); GRO-alpha (human) and KC (murine)).
Therefore, mechanisms that may be identified via a syngeneic mouse model may not
directly translate to humans [158]. Xenograft models permit the study of human cancer
cells in an immune-compromised host such that mechanisms specific to human cancer
cell progression may be studied. In many cases, human and mouse cells are capable of
uninhibited crosstalk [158,159]. However, xenograft models do not permit the study of the
immune system with cancer progression.
Syngeneic and xenograft models may further be broken down based on the route
of injection, specifically via the orthotopic, intracardiac, or intratibial route [160]. In an
orthotopic model, cancer cells or fragments are implanted into the same anatomic location
from which the cancer originated; i.e., breast cancer cells inoculated into the mammary
gland or prostate cancer cells inoculated into the prostate of a mouse. While orthotopic
models are very beneficial in studying primary cancer progression, many times, a primary
tumor may out-pace the growth of any metastases that may arise. In these cases, primary
tumors may be removed upon reaching a certain size, subsequently allowing metastases
in secondary sites to progress. Depending on the growth of the inoculated cancer cells,
progression to metastasis in orthotopic models may be prolonged, requiring multiple
months of study [161]. Experimental metastasis models permit the investigation of steps
involving the trafficking of cancer cells to secondary sites, as well as investigation of late-
stage metastases. Intracardiac injections recapitulate cancer cell trafficking and homing
to secondary organs via the vasculature due to the cancer cells being directly injected
into the left ventricle of the heart, which bypasses pulmonary circulation [160]. Several
laboratories have developed bone-tropic cell lines utilizing intracardiac mouse models,
which more closely mimic bone metastases in humans [162,163]. In the majority of cases,
intracardiac injections are carried out in a xenograft model due to fluorescent labeling of
inoculated cancer cells for tracking and retrieval for ex-vivo analysis. Finally, intratibial
injections are a model of established disease whereby cancer cells are directly injected into
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the trabecular bone of the tibia of mice. Tumors rapidly form, permitting the study of the
bone microenvironment during late-stage disease [160].
5.2.2. Three-Dimensional Tissue-Engineered Models to Study Cancer–Bone Interactions
during Disease Progression
Current models to investigate complex cancer cell–bone interactions include tissue-
engineered bone constructs (TEBCs), bone-on-a-chip (BC) bone tissue models, bioreactors
for continuous culture, three-dimensional printed bone matrix scaffolds, hydrogels, and
extramedullary bone models [164–166]. While these models replicate physiological systems
better than standard two-dimensional cell culture due to their biophysical properties, all
of these models fall short of being able to fully recapitulate the complexity and cellular
crosstalk that occurs in the bone–tumor microenvironment. As a result, many investigators
use a combination of 2D cell culture, 3D tissue-engineered models, and in-vivo models to
investigate specific steps of the metastatic cascade.
Hydrogel Tissue Constructs
Hydrogels can be used in both two- and three-dimensional formats and are available
as either natural (i.e., collagen) or synthetic (i.e., polyacrylamide) materials [167–170]. Of
the types, three-dimensional hydrogels best mimic native bone, recapitulating tissue stiff-
ness and bone’s elastic modulus, which most closely represent the mechanotransductive
properties of the skeleton [164]. Furthermore, three-dimensional hydrogels permit the em-
bedding of cells to be studied, which facilitate the study of cellular migration and invasion
through a matrix. This also enables seeded cells to resemble their normal morphology
in-vivo, thus allowing for better representation of physiologic events that occur during
cell–cell and cell–matrix contact. While beneficial, the increased complexities involved
in the use of cell-containing three-dimensional hydrogels (e.g., viability-maintaining fab-
rication techniques, crosslinking, and nutrient diffusion) may increase resource needs
relative to more simple two-dimensional models (e.g., gel-coated polystyrene) as well
as create technically challenging analysis via full thickness penetration of the hydrogel
for imaging [167,170]. Because of these limitations, two-dimensional hydrogels are ben-
eficial for easier cell observation and analysis, as well as the ease of manipulation of
microenvironmental conditions. Two-dimensional hydrogels are also well established.
A major disadvantage of two-dimensional hydrogels, though, is the inability to permit
three-dimensional tissue structure, including flattened cell morphology, forced cell polarity
(i.e., cells seeded on top of a hydrogel as opposed to within), and a high matrix stiffness
due to the conformation of the hydrogel being flat [164].
Bone-Like Scaffolds
Bone-like scaffolds are one 3D model system frequently used to model the bone mi-
croenvironment [107,117]. These models are capable of recapitulating the rigid extracellular
matrix of bone. Polymers such as poly-(ε-caprolactone) (PCL) [114,115], polylactic acid
(PLA), or PCL/PLA blends [116] have been used to print 3D scaffold structures onto which
cells of interest are seeded. PCL, in particular, is an FDA-approved biocompatible and
bioresorbable scaffold that has been used in the past as a three-dimensional scaffold for
craniofacial bone grafts, but is now being used in other applications [171,172]. Our labora-
tory in particular has used PCL-based scaffolds as model systems in which GFP-labeled
triple negative breast cancer cells were cultured [33]. We showed that the cancer cells were
capable of infiltrating the depth of the scaffold while proliferating, and were also capa-
ble of establishing vascular networks through the formation of blood vessels [33]. Other
studies have shown that PCL blended with PLA mimics bone architecture well, whereby
osteosarcoma cells were capable of seeding and proliferating in scaffolds generated with
these materials [165,173,174]. Thus, biomimetic synthetic polymers are a useful tool that
effectively models both the biomechanical properties and architecture of the bone niche.
Furthermore, these models allow for the manipulation of the niche via exchange of seeded
cells of interest.
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Bioreactor-Based Engineered Tissue
Bioreactors are another useful tool to specifically examine bone–tumor interactions un-
der long-term culture conditions [118–120]. While these models are mainly limited to study-
ing cellular behavior in-vitro, they do offer the flexibility of long-term cell growth/crosstalk
(i.e., 6+ months). Vogler, Mastro, and colleagues designed a 3D bioreactor capable of
generating crosstalk upon long-term culture (up to 120 days) of both murine and human
osteoblast cell lines. Importantly, these cells displayed characteristics of normal osteoblasts
throughout their growth [118]. Furthermore, that same model system was used to mimic
breast cancer colonization in bone whereby a tri-culture of osteoblasts, osteoclasts, and
human breast cancer cells recapitulated events observed during the “vicious cycle of breast
cancer metastasis”, including increased osteoclast activity, along with a decrease in os-
teoblast response, decreased matrix thickness, increased matrix resorption, and increased
cancer cell proliferation [119]. Both human and murine cells were capable of growth in
the bioreactor.
Humanized Biomaterial Implants
Finally, other groups have developed novel humanized biomaterial implants to serve
as new platforms for the study of the bone niche. Andreeff and colleagues developed
an extramedullary bone (EMB) model using mesenchymal stromal cells and endothelial
colony-forming cells to recapitulate the hematopoietic and bone marrow microenviron-
ments [30]. Importantly, this was the first development of a genetically controlled human
bone marrow microenvironment capable of engrafting into NOD/SCID/IL-2r gamma
null (NSG) immunocompromised mice. Unlike prior models to study the human bone
marrow microenvironment, the EMB closely mimics human disease in-vivo, provides a
robust hematopoietic environment, and can serve as a representative assay for modeling
cancer metastases to bone [30]. Importantly, this model effectively recapitulated leukemia
cell seeding and proliferation in a human bone marrow microenvironment, as well as
permitted cancer cell metastasis to the ends of long bones; a preferential site of cancer
cell invasion [30]. Several years later, Andreeff and colleagues refined this mouse model
to include a humanized bone-chip implant whereby freshly isolated human bone frag-
ments were collected from patients undergoing hip replacement surgery and mixed with
Matrigel™ [29]. Four weeks post-implantation into the flanks for NSG mice, the human
bone implants developed their own vasculature. To investigate leukemia engraftment and
the impacts of leukemia on osteogenic differentiation, Molm13 leukemia cells expressing
GFP and luciferase were injected via the tail vein and strongly engrafted into the human
bone implant as early as 10 days post-injection [29]. Similarly, the Lee group utilized a bio-
engineering approach to create genetically engineered scaffold microenvironments using
human bone stromal cells [27,28]. The human bone marrow stromal cells were genetically
engineered to stably express human cytokines (including TNF-alpha) or human growth fac-
tors (including VEGF) important for bone remodeling and were embedded into 3D porous
hydrogel scaffolds. This permitted the generation of a human soluble factor-enriched
microenvironment. The seeded scaffolds were then implanted into immunocompromised
mice and stromal cell engraftment and proliferation were investigated [27].
In an effort to merge principles from the EMB model and genetically engineered bone
scaffold model, our laboratory seeded PCL scaffolds (Figure 1A) coated with Matrigel™
with GFP-labeled MDA-MB-231 human metastatic breast cancer cells admixed at a 1:1 ratio
with either naïve MC3T3-E1 osteoblasts (OB) engineered to express tdTomato or educated
osteoblast (EO) cells engineered to express tdTomato [175]. The seeded scaffolds were
then cultured for 12 days during which we monitored the engraftment of both the MDA-
MB-231GFP breast cancer cells and either MC3T3-E1-tdTomato osteoblasts or tdTomato-
EO cells over time using fluorescence imaging. As seen in Figure 1, MDA-MB-231-GFP
breast cancer cells and either MC3T3-E1-tdTomato osteoblasts (Figure 1B–E) or tdTomato-
EO (Figure 1F–I) cells can clearly be seen proliferating, spreading out, and positioning
themselves adjacent to each other within the scaffold over time [175].
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Scaffolds were implanted into the flanks of NSG mice 13 days after cell seeding. Mice
were monitored via an In-Vivo Imaging System (IVIS) non-invasive intravital imaging for
2 months, where cancer cell proliferation in the scaffold can be seen (Figure 2A,G) [175].
Mice were humanely euthanized, and scaffolds and femurs (site of preferential metastasis)
harvested for analysis. Ex-vivo scaffold analysis revealed well-formed tumors composed
of either MC3T3-E1-tdTomato osteoblasts (Figure 2B) or tdTomato-EO cells (Figure 2H).
Interestingly, even though scaffolds were originally seeded with a 1:1 admix of GFP-cancer
cells plus either MC3T3-E1-Tdtomato osteoblasts or tdTomato-EO cells, less proliferation
of MC3T3-E1-tdTomato osteoblasts was apparent, as evidenced by less expression of
tdTomato: ~38% of the tumor (and ~62% of the tumor composed of GFP-breast cancer
cells; Figure 2B), when compared to tdTomato-EO cell engraftment of the tumor: ~55% of
the tumor (and ~45% of the tumor composed of GFP-breast cancer cells; Figure 2H) [175].
These results corroborate our prior findings that EO cells suppress metastatic breast cancer
cell growth [85]. Both tumors exhibited blood vessel formation (white arrows, Figure 2B,H).
Surprisingly however, we were unable to recapitulate breast cancer cell metastasis to the
bone, whereby no femurs showed evidence of MDA-MB-231GFP metastatic breast cancer
cells by fluorescence microscopy (Figure 2C–F,I–L) [175]. This phenomenon had been
observed as part of the EMB model as per Andreeff and colleagues [30].
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Whereas these model systems recapitulate select steps of the metastatic cascade
or closely model aspects of human disease, none sufficiently combine both a human-
ized/human bone icroe vironment with appropriate stromal cells, architecture, and me-
chanical forces along with a syste that demonstrates all steps of a human metastatic cas-
cade. Thus, three-dimensional bioprinted model systems address this gap in
the research.
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6. Bioprinting
6.1. Basis of Bioprinting
Bioprinting provides a novel additive manufacturing technique to fabricate prescribed
architectures formed through layer-by-layer construction of biological materials and living
cells [176]. Cells can be impregnated into the resultant extracellular matrices post-printing
using traditional cell seeding techniques or incorporated directly into the printing process
to produce precursor tissue constructs. Such constructs can then be directly implanted
in-vivo for regenerative medicine applications or cultured in-vitro to produce mature,
biomimetic tissues, holding promise for breast cancer applicatio s [177].
Although bioprinting was initially established in the form of cytoscribing, a modified
inkjet printing technique allowing the deposition of biologic materials for cell adhesion
and growth into planar geometries that could be individually stacked and adhered [178],
the field quickly evolved to produce in-situ three-dimensional structures. Along with
developing inkjet techniques, the rise of rapid fabrication processes such as fused depo-
sition modelling (FDM), stereolithography (SLA), and selective laser sintering (SLS) has
allowed for more complex three-dimensional shapes [179]. Most recently, the incorporation
of living cells into printable biological materials (i.e., bioinks) and modifications in the
printing process to maintain cell viability have led to advanced constructs with patterned
cellular and structural elements with bioactivity [179]. Thus, current bioprinting technolo-
Cancers 2021, 13, 507 13 of 28
gies allow for an expansive array of promising applications including providing research
environments for the study of stem and cancer cell behavior [16,180–182], platforms for
drug screening, delivery, and production [183,184], and engineered tissues/organs for
transplantation [185].
The advantages of bioprinted constructs over traditional two-dimensional cell culture
are numerous. The complex, three-dimensional architectures allow for micron-scale preci-
sion of the structural environment housing cells, thereby directing their native functions in
a manner difficult to achieve with two-dimensional cell culture [186]. Macroscopic geome-
tries can be customized in size and shape identical to native tissues and organs based on
patient specific CT and/or MRI data. The biochemical properties of the substrate materials
and potential for conjugation with other biomolecules not only support tissue-specific cell
function, but can control vascularization, nerve integration, and maturation of engineered
tissue [186]. In addition, the recent availability of desktop bioprinting systems with easily
accessible hardware and software systems presents a practical option for a fast, low-cost 3D
bioactive construct production [187], further supporting the development of personalized
tissues for research and regenerative medicine [188].
6.2. Bioprinting Techniques
3D bioprinting offers the opportunity to manufacture an array of engineered tissues
with varying physical and biochemical properties to suit individual applications. Methods
for printing include inkjet, extrusion-based laser-induced printing, and projection stere-
olithography (Figure 3). Each method has unique benefits and limitations and the most
appropriate printing technique is dependent on the specific operational requirements of
the engineered tissue produced [189].
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Figure 3. 3D bioprinting techniques. (A) Extrusion bioprinting: nozzle-based continuous layer-
by-layer deposition of bioink using pneumatic pressure-, screw-, or pledged-based mechanisms.
(B) Inkjet bioprinting: nozzle-based layer-by-layer deposition of bioink droplets using thermal heat
or mechanical pulses to acoustic waves. (C) Projection stereolithography bioprinting: layer-by-layer
photoinduced curing of bioink using UV light. (D) Laser-induced forward transfer bioprinting:
laser-based depositing bioink droplets through energy transfer from the absorption donor layer to
the bioink layer.
Extrusion-based manufacturing (Figure 3A) is the most common method of bioprint-
ing, whereby the substrate cell +/− biomaterials are deposited through a thin nozzle
in a continuous flowing fashion onto the build plate through the application of force
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on the bioink reservoir. Various methods for force generation exist, resulting in a range
of extrusion-based bioprinter designs, including pneumatic-based (air pressure), piston-
driven (vertical force), and screw-driven (rotational force) dispensing techniques [190].
Scaffold constructs can be printed from a homogeneous cell-laden biomaterial ink directly,
with dual extrusion heads allowing for independent biomaterial deposition followed by
targeted cell placement within the structure, or as a cell-free scaffold with manual cell
seeding post-printing [190]. Thus, there is an expanded range of materials that can be used
as substrates (e.g., those requiring washing prior to cell seeding to enhance viability) and
more precise control over cell distribution with the resultant matrices. The resolution of
micro-extrusion bioprinting is in general from 100–500 µm, though it can be as small as
50 µm with the incorporation of microfluidics in the system [179,191]. The extrusion-based
method allows for fabrication of structures with bioinks of higher viscosities and cell
densities (e.g., greater than 1 × 106 cells/mL [190]), however, as a nozzle-based system it is
also associated with shear stress, potentially impacting cell viability [179].
Inkjet bioprinting (Figure 3B), the first method developed, involves dispensing bioink
through a thin nozzle in 1–100 µL volumes in a precise three-dimensional pattern [192].
Also known as the drop-on-demand method, the droplets are discharged by either an
internal vapor bubble generated by an external thermal heating element or an acoustic
wave generated by mechanical pulses of a piezoelectric element allowing for a resolution
of 50 µm [177,179]. Printing using this technique is fast (up to 10,000 droplets/second) and
relatively low cost vs. other methods, but input substrate options and cell densities may
be limited secondary to nozzle clogging with more viscous bioinks [177,179]. Moreover,
the heat, acoustic pressure, and high shear rates generated can compromise cell viability,
although limiting exposure time may improve cell survival [179,187].
Projection stereolithography (SLA; Figure 3C) is another layer-by-layer fabrication
method for bioprinting which involves solidifying liquid biocompatible resins by pho-
topolymerization under irradiation [192,193]. This method is therefore limited to special-
ized, photocurable bioinks [177]. Although SLA produces mechanically robust constructs,
uncured bioink can seep into open spaces, making hollow structures (e.g., vessels) particu-
larly challenging to execute [193].
Laser-induced printing (Figure 3D) does not involve a nozzle, circumventing some
of the limitations of the previously described methods. Instead, a glass slide coated with
an ink solution and a laser absorption layer consisting of a metal or metal oxide is ablated
by a laser at distinct location (40–100 µm resolution), generating a pressure that ejects ink
onto the substrate [189]. Also known as laser-induced forward transfer, it can print viscous
bioinks at very high resolution, although at very high costs and temperatures that may risk
heat-induced cell death [189].
In an effort to maintain the structural integrity of some complex 3D structures, support
material may be necessary to improve the printability of certain bioinks and attain more
accurate print results [194]. A suspension-based 3D bioprinting technique, known as
freeform reversible embedding of suspended hydrogels (FRESH), allows for the printing of
soft hydrogels in a support bath of a thermoreversible gel that can be subsequently melted
away, as depicted in Figure 4 [195]. The extrusion and embedding of the bioinks into
the gel in essence diminish gravitational effects, allowing for print geometries otherwise
unattainable with certain soft biomaterials, as they would ordinarily collapse in air [196].
FRESH-printed structures require some post-print processing, including washing away
the excess gelatin post-melting [196]. This noteworthy technique has led to improved
print resolution and reliability, and the potential to engineer versatile unsupported print
architectures and larger advanced tissue scaffolds [195].
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Figure 4. Freeform reversible embedding of suspended hydrogels (FRESH) bioprinting technique.
Hydrogel bioink deposited via extrusion bioprinting into a thermoreversible gelatin slurry support
bath with a Bingham plastic rheology allows for structural suspension of bioprinted tissue scaffolds
to mitigate the force of gravity. An overnight post-print heat release in a 37 ◦C incubator melts the
gelatin, leaving the 3D structure behind.
6.3. Bioinks
Bioinks are substrates used to produce 3D printed constructs containing cells and/or
extracellular matrix components. The composition of the bioink plays a critical role in
maintaining cell viability during the printing process and providing the structural integrity
necessary to support function post-production [188]. For example, hydrogel-based cell-
laden bioinks can protect cells from potentially harmful desiccation and shear forces during
the printing [197]. In order to achieve the ideal balance between cell survival and the
desired construct structural parameters, careful consideration of not only cytocompatibility,
but biocompatibility, bioactivity, and local geometry must be considered to support cell
differentiation and growth [189]. Moreover, considerations of printability (e.g., viscosity)
along with final overall construct mechanical strength and degradation characteristics
(e.g., crosslinking) also require attention when determining the resultant construct physical
properties [189].
The three most common bioink options include cell-laden hydrogels, ECM-based
inks, and cell suspensions [189]. Cell-laden hydrogels closely mimic/recapitulate the
cellular microenvironment by incorporating bioactive compounds and growth factors and
permitting the diffusion of nutrients [198]. Natural hydrogels, such as collagen, fibrin,
gelatin, and hyaluronic acid are inherently bioactive and simulate the native structure of
the ECM, whereas synthetic hydrogels, such as pluronic (poloxamer) and polyethylene
glycol (PEG), are mechanically tunable and can support the delivery of added bioactive
cues [189,199]. While such hydrogels allow for highly reproducible structures, their limited
mechanical strength can be an issue, often augmented by FRESH techniques during and
crosslinki g fter printing the polymers [199].
Single-component hydrogels prepared as bioinks may not adequately provide the
composition and fu ction f native ECM in 3D models, as they lack the complex envi-
ronment th t allows for cell engraftment, migration, signaling, and function [200,201].
Decellularized ECM (dECM) off rs organ-specific biochemical cues from native ECM to
improve cell proliferation and survival [200]. The use of dECM in bioi ks can be enhanced
by the addition of chemical and biological crosslinking agents to strengthen the scaffold
mech nically and improve bioactivity [200]. Ma tainin the viscoelastic materials of the
tissue is vital to gene ating a sufficient model of he native tissue. Collagen is a common
bioink and major ECM protein as t is easily crosslinked using methods, such s tempera-
ture and pH, however, its gelation time and unstable mechanical properties are barriers
for use in 3D bioprinting [202]. dECM hydrogels are a promising method for constructing
functional tissues and organs with multicellular compositions.
The incorporation of specific bioactive additives allows for manipulation of the me-
chanical and physiological properties of printed constructs [189]. Hydroxyapatite (HA)
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and bone morphogenetic protein 2 (BMP-2), two common bioink additives, are known
for promoting osteoinductivity and osteoconductivity, and can also confer structural and
mechanical properties to bioprinted bone constructs [179]. BMP-2 has been shown to
induce mesenchymal stem cells toward osteogenic differentiation [203], and when loaded
into hydrogel-based 3D printed constructs, demonstrated sustained release and improved
osteogenic differentiation and bone formation effects in-vitro and in-vivo [204].
HA has been shown to regulate the behavior of cells, specifically osteoblast adhesion
on nanocrystalline hydroxyapatite (nHA) nanoparticles [205], and to improve normal bone
formation, through the stimulation of cell proliferation and osteogenic differentiation [206].
The incorporation of nHA with gelatin methacrylate (GelMA) into bioprinted bone matri-
ces in a study by Xuan Zhou and colleagues showed osteoblast and mesenchymal stem
cell (MSC) proliferation and improved overall compressive stress of the resultant matrix
constructs [207]. Hyperelastic bone (HB), a recently commercialized extrudable bioink
made up of hydroxyapatite and PCL or poly(lactic-co-glycolic acid) offers a promising
material for bioprinted bone applications [208]. In addition to its local effect on cell func-
tion, printed HB constructs can be successfully stretched, cut, and sutured to a soft tissue
(such as tendon), making it a promising candidate for applications in tissue replacement
surgeries [208]. Synthetic scaffolds constructed from this porous substrate have been used
to study bone regeneration in-vivo [209]. Fluffy–poly(lactic-co-glycolic acid) and hyper-
elastic bone scaffolds were compared against a negative control and positive control of
autologous calvarial bone for the treatment of calvarial defects in rats. The hyperelastic
bone was shown to be effective for bone regeneration and for inducing bone formation
in-vivo in the defects. Hyperelastic bone has also been implanted in non-human primates
to model biocompatibility and fusion rates, and successfully demonstrated vascularization
and no significant immune response [210,211].
6.4. Applications of Bioprinting in Cancer
6.4.1. 3D Printed In-Vitro Models
Three-dimensional bioprinting presents an opportunity to develop functioning tissue
beyond just structural scaffolds by incorporating cells into the printable bioinks [179].
Current applications of bioprinting include three-dimensional extracellular matrix compo-
nents, organ structures, regenerative tissue grafts, and disease models [198]. FRESH 3D
bioprinting can help to optimize the fabricated microenvironments, by controlling print
resolution, improving cell viability, and supporting delicate architectures necessary for
certain in-vitro cancer research models. For example, Lewicki et al. used the technique to
optimize human neuroblastoma cell-laden hydrogels of low viscosity [212]. Applications
of dECM-based bioinks hold particular promise in studying ECM components of the tumor
microenvironment (TME) and tumor–ECM interplay [213]. Quickly polymerizable dECM
bioinks allow for tunable stiffness in applications such as 3D bioprinted kidney cancer
constructs in which 3D bioprinted dECM microtumor models were achieved with refined
control over both the multicellular populations and dECM bioink deposition [213]. Notably,
bioprinted matrices constructed from various substrates with or without FRESH methods
can provide viable in-vitro models for understanding cell behaviors and interactions in
cancer. For example, extrusion-based printing of bioinks composed of HeLa cells and
gelatin/alginate/fibrinogen hydrogels allowed for the development of a 3D cervical tumor
model [214]. Compared with cells in planar 2D cultures, HeLa cells in the 3D environment
showed more behavioral similarity to native cancer cells, including higher cell proliferation,
matrix metalloproteinase (MMP) protein expression, and chemoresistance [215].
Increasing numbers of bioprinted models are being developed as higher fidelity
systems to study key aspects of cancer development and progression in a variety of tis-
sues/organs. Tang et al. used bioprinting techniques to develop a complex in-vitro 3D
glioblastoma model to allow for exploration of the role of immune components within
the tissue microenvironment [216]. The glioblastoma stem cells, resident CNS cells, and
macrophage precursors better resembled the invasive cell types of patient tumor tissue
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in the bioprinted models as opposed to sphere cultures [216]. Hakobyan et al. used laser-
assisted bioprinting to generate 3D pancreatic cell spheroid arrays to replicate the ini-
tial stages of pancreatic ductal adenocarcinoma (PDAC) as a high-throughput, repro-
ducible model for the study of pancreatic cancer progression and potential therapeutic
approaches [217]. Novel model systems are emerging using 3D bioprinting techniques to
study other neurological tumors, as well as liver, breast, and skin cancers, that allow for the
in-vitro study of susceptibility and resistance to chemotherapeutics for predictable human
response [218].
6.4.2. Bioprinted Models for Breast Cancer Metastasis
Bioprinting offers a biomimetic in-vitro three-dimensional cancer culture system capa-
ble of modeling cell colonization, tumor growth, and response to therapies. The accuracy of
the architecture, vascularization, and composition of the tumor microenvironments demon-
strated by bioprinted models reinforces the progress in this domain beyond conventional
tissue-engineered constructs. However, cell viability presents a great challenge in the bio-
printing process, as the high-throughput processing can directly impact cell proliferation.
Recent advances in the use of bioprinting to model cancer microenvironments include
tumor fabrication [51,52], allowing for successful modeling of cancer cell interactions.
One of the most crucial elements of an in-vitro cancer model is the scaffold, which
emulates the extracellular matrix of the cancer microenvironment. Bioprinted matrices
allow for the fabrication of those scaffolds, permitting continued study of the metastasis of
breast cancer in bone. In-vitro models provide limitless opportunity for the study of cancer
cell interactions and therapeutic advances. Current applications of bioprinting in the study
of breast cancer metastasis in bone include bioprinted bone matrices to investigate cancer
cell interactions, cell migration, and drug resistance.
Cell-laden bone matrix scaffolds to study the interaction of breast cancer cells with
osteoblasts or mesenchymal stromal cells were developed by Zhou and colleagues [37]. The
bone matrices were printed with a stereolithography bioprinter, using a bioink consisting
of GelMA hydrogel and nanohydroxyapatite (nHA) (incorporated to simulate native
bone tissue), and a printable bioink with a cell suspension consisting of osteoblasts or
mesenchymal stromal cells. Breast cancer cells were seeded on the surface of the stromal
cell-laden matrices and co-cultured with osteoblasts or mesenchymal stromal cells for
5 days. In the co-culture environment, breast cancer cells showed enhanced proliferation
but drastically inhibited the osteoblast/mesenchymal stromal cell growth. These data
suggest that nHA facilitates interactions between the bone stromal cells and breast cancer
cells [37].
Exploring the crosstalk between different cell types, Zhu et al. conducted a study
observing the interaction between human fetal osteoblasts (hFOBs) and metastatic breast
cancer cells on a 3D bioprinted artificial bone matrix, as depicted in Figure 5 [219]. The
matrix also contained the calcium phosphate nHA as it is associated with metastatic breast
cancer progression to bone [219]. Human breast cancer cells co-cultured with hFOB cells on
the matrix impacted the morphology and proliferation rate of both cell types, in addition
to enhanced IL-8 secretion, a pro-inflammatory chemokine that contributes to angiogenesis
and tumorigenesis. Notably, the presence of metastatic breast cancer cells induced height-
ened osteoblastic IL-8 expression. Furthermore, the addition of the nHA to the bone matrix
increased the overall proliferation rate of breast cancer cells in a concentration-dependent
manner [219]. Beyond examining cellular morphology, proliferation, and cytokine expres-
sion, indirect and 3D bioprinted constructs may also be used to assay alterations in cellular
crosstalk, including osteoblast differentiation and cellular protein expression, as well as
cellular engraftment into the 3D bone matrix (Figure 5). Overall, these data suggest that the
composition of the 3D bioprinted matrix is crucial to fully recapitulating cellular in-vivo
behavior of metastatic cancer cells in the bone tumor microenvironment.
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Figure 5. 3D bioprinted bone tissue constructs to study crosstalk between osteoblasts and breast
cancer cells. Indirect transwell co-culture and 3D co-culture of breast cancer cells and osteoblasts on an
artificial nanohydroxyapatite (nHA) bone matrix fabricated by stereolithography-based 3D printing.
These model systems permit the study of cellular crosstalk between osteoblasts and breast cancer
cells as it relates to cellular morphology, proliferati n, oste blast differentiation, expression of soluble
factors, alterations in cellular protein expression, and cellular engraftme t into the bone matrix.
7. Conclusions and Future Exploration
Although 3D bioprinting allows for the precise control of scaffold architecture, these
techniques present many challenges in ensuring ideal cell function. Moving forward,
physical and biophysical properties of 3D bioprinted scaffolds, including scaffold–matrix
stiffness, “tunability” of the scaffold composition, which may include the addition of
growth factors and metabolic products native to an endogenous extracellular matrix to
facilitate cell growth, porosity of the scaffold to ensure successful cellular attachment
and proliferation, alterations in scaffold size, and alterations in scaffold geometry (e.g.,
honeycomb vs. grid, etc.), as well as other mechanical properties, should be assessed to
optimize these factors for successful cellular engraftment and growth [220–225]. Further-
more, optimization of a stable scaffold capable of in-vivo implantation with resistance
to degradation over time may be critical to the development of long-term viable cellular
systems and matrix vascularization.
Interestingly, it has been found that certain scaffold geometries are superior to others
with respect to cellular engraftment and viability over time. In particular, Foresti et al.
developed a well-defined scaffold with complex architecture that was vascularized and
capable of long-term cellular viability [226]. The authors additionally investigated the
biological responses of cells seeded on several different scaffolds of complex geometries
and determined certain geometries were superior to others for cellular engraftment and
proliferation as well as the ability of the scaffold to retain its shape—in some cases for up
to 23 months while in culture [226]. Wang et al. additionally investigated how modulating
the parameters of a gelatin/alginate hydrogel scaffold, including using various geometries,
pore volumes, volume porosity, and surface areas, affected the cell viability, distribution,
morphology, proliferation, and expression of cell-specific markers of C3A liver cells [223].
The authors determined that the geometry of PO250+ (fine checkerboard), with a pore size
of 250 µm, was optimal towards eliciting strong cell proliferation and viability, as well
as causing the expression of the liver-specific mRNA CYP3A4 and protein albumin [223].
With specific reference to the cellular behavior of cancer cells, Hanumantharao et al. carried
out an interesting study examining how different topographical features and mechani-
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cal properties of PCL scaffolds influenced human ER+ and triple negative breast cancer
cells [227]. The authors found that human MCF-7 ER+ breast cancer cells proliferated
well on a variety of different scaffold topographies, where the MCF-7 cells had a higher
rate of proliferation on scaffolds with low Young’s modulus and stiffness. On the other
hand, human MDA-MB-231 triple negative breast cancer cells preferred scaffolds that had
a high matrix stiffness [227]. These results suggest that cancer cells respond to changes
in scaffold stiffness, mechanical properties, and topography, which should be considered
when developing a 3D bioprinted scaffold to model the tumor microenvironment.
Importantly, scaffold “tunability” may be extremely useful when investigating tumor–
stromal cell crosstalk and the biophysical properties of the extracellular matrix. Recently,
3D bioprinted scaffolds have been developed that are capable of the controlled release of
growth factors that affect angiogenesis and osteogenesis in the bone microenvironment.
Specifically, Freeman et al. developed 3D bioprinted constructs to deliver VEGF and
BMP-2 with distinct spatiotemporal release profiles to enhance the regeneration of large
bone defects [228]. Importantly, the properties of the 3D bioprinted constructs were
“tunable” in that (1) the release of VEGF and BMP-2 could be slowed or accelerated, and
(2) the distribution of release of VEGF and BMP-2 could be localized or eluted in a spatial
gradient [228]. In a similar fashion, Sun et al. developed a 3D bioprinted scaffold loaded
with connective tissue growth factor and transforming growth factor beta 3, then seeded
with mesenchymal stromal cells and implanted into mice to facilitate the regeneration
of an intervertebral disc [229]. Importantly, the authors showed that the reconstructed
intervertebral disc exhibited properties similar to a native disc bone, with corresponding
histological and immunological phenotypes [229]. Given that 3D bioprinted scaffolds may
be loaded with specific growth factors at different concentrations, these models represent
a unique and novel way to study interactions between the tumor and stromal cells in
different environmental conditions that recapitulate different stages of disease.
Furthermore, 3D bioprinted scaffolds may also be valuable for their ability to both
elute drugs into the niche in a sustained manner over time and manipulate the expression
of specific factors in the microenvironment. For example, Wu et al. developed a novel
biocompatible scaffold for endothelial cell repair in cardiovascular disease [224]. The team
loaded dimethyloxalylglycine (DMOG) into biocompatible ink with a final concentration
of 30% (w/w). Over time, in culture with aortic endothelial cells, the scaffold exhibited
sustained release of DMOG into the media, which induced the expression of HIF-1 alpha by
the aortic endothelial cells. HIF-1 alpha then elicited the transcriptional activation of VEGF,
a HIF-1 alpha target gene, suggesting that implantable 3D bioprinted scaffolds loaded with
drugs can aid in the repair of endothelial cells in cardiovascular disease [224]. Using the
same principle and taking it a step further, the same idea can be applied to manipulating
the tumor microenvironment to elicit the expression of certain tumor suppressor molecules,
promote an antitumor immune response, or deliver localized therapeutic treatment. The
ability to tailor and customize both the environmental response as well as drug loaded into
the printed scaffold would be of great benefit to more efficiently target specific cells in the
tumor niche over time.
The use of bioprinted constructs introduces a significant high-throughput, low-cost
advance in future cancer research that provides a novel perspective for cancer cell growth
determinants and potential therapeutics. The incorporation of growth factors and biophysi-
cal properties of the ECM could allow researchers to better understand the 3D breast cancer
microenvironment through these native-like tumor platforms.
As research progresses towards optimization of the matrix geometry, and more phys-
iologically accurate ECM, researchers come closer to achieving in-vivo conditions for
evaluating breast cancer cell behavior and tumor growth. Achieving a matrix that exhibits
native characteristics of tumor–stromal cell crosstalk in-vivo will lead to opportunities to
study interactions between breast cancer cells and bone stromal cells, metastatic progres-
sion, and response to drug therapy. Drug screening and therapeutic cancer drug response
testing on 3D bioprinted bone matrices could also reduce the time to screen candidate
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therapeutics when compared to in-vivo systems and reduce the number of animal models
used in testing, thus providing a viable alternative to traditional animal models.
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